Arrowhead Pharmaceuticals Inc. (ARWR)

27.72
0.20 0.73
NASDAQ : Health Technology
Prev Close 27.52
Open 27.70
Day Low/High 27.35 / 28.00
52 Wk Low/High 10.41 / 28.46
Volume 997.72K
Avg Volume 2.06M
Exchange NASDAQ
Shares Outstanding 94.81M
Market Cap 2.61B
EPS -0.70
P/E Ratio 392.86
Div & Yield N.A. (N.A)
Arrowhead Research Publishes White Paper On RNAi Delivery Technology Acquired From Roche

Arrowhead Research Publishes White Paper On RNAi Delivery Technology Acquired From Roche

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of a white paper providing an overview...

Arrowhead Research Appoints Brendan P. Rae, Ph.D., J.D., Chief Business Officer

Arrowhead Research Appoints Brendan P. Rae, Ph.D., J.D., Chief Business Officer

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that it has appointed Brendan P.

Vascular Research Further Validates The Drug Development Programs Of Arrowhead Research Subsidiary Ablaris Therapeutics And Alvos Therapeutics

Vascular Research Further Validates The Drug Development Programs Of Arrowhead Research Subsidiary Ablaris Therapeutics And Alvos Therapeutics

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that a paper further validating the drug development programs of Ablaris Therapeutics, Inc.

Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer

Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has appointed Bruce Given, M.

Arrowhead Research Corporation Acquires Roche RNA Assets And Site

Arrowhead Research Corporation Acquires Roche RNA Assets And Site

Arrowhead Research Corporation (NASDAQ: ARWR), today announced that it has acquired RNA therapeutics assets from Roche (SIX: RO, ROG; OTCQX: RHHBY) including the state-of-the-art research site in Madison, WI.

Arrowhead Research Corporation Completes $5.5 Million Private Placement

Arrowhead Research Corporation Completes $5.5 Million Private Placement

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that on September 30, 2011, it closed a private placement of approximately 14.

Arrowhead Reports Fiscal 2011 Third Quarter Financial Results

Arrowhead Reports Fiscal 2011 Third Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011 third quarter...

Arrowhead Research To Report Fiscal 2011 Third Quarter Financial Results And Host Conference Call On Monday, August 8, 2011

Arrowhead Research To Report Fiscal 2011 Third Quarter Financial Results And Host Conference Call On Monday, August 8, 2011

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2011 third quarter ended June 30, 2011, on Monday, August 8, 2011 at 4:30 p.

Arrowhead Research Announces Oncology Expert Timothy J. Triche To Join Calando Scientific Advisory Board

Arrowhead Research Announces Oncology Expert Timothy J. Triche To Join Calando Scientific Advisory Board

Arrowhead Research Corporation (NASDAQ:ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that Timothy J.

Arrowhead Research To Present At Two Nanomedicine-Focused Events In London

Arrowhead Research To Present At Two Nanomedicine-Focused Events In London

Arrowhead Research Corporation (NASDAQ:ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and Chief Executive Officer ...

Arrowhead Research President & CEO Christopher Anzalone Featured In The Wall Street Transcript Interview

Arrowhead Research President & CEO Christopher Anzalone Featured In The Wall Street Transcript Interview

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and CEO Christopher Anzalone, Ph.

Arrowhead Receives Additional 180 Day Grace Period To Comply With The NASDAQ $1.00 Minimum Bid Requirement

Arrowhead Receives Additional 180 Day Grace Period To Comply With The NASDAQ $1.00 Minimum Bid Requirement

In first graph, first sentence of release, date should read: June 7, 2011 (sted June 7, 2017).

Arrowhead Reports Fiscal 2011 Second Quarter Financial Results

Arrowhead Reports Fiscal 2011 Second Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011 second quarter...

Arrowhead Research To Report Fiscal 2011 Second Quarter Financial Results And Host Conference Call On Thursday, May 12, 2011

Arrowhead Research To Report Fiscal 2011 Second Quarter Financial Results And Host Conference Call On Thursday, May 12, 2011

Arrowhead Research Corporation (NASDAQ:ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that it will report its financial results for the fiscal...

Arrowhead Research To Present At The 2011 MDB Capital Group Bright Lights Conference On May 10

Arrowhead Research To Present At The 2011 MDB Capital Group Bright Lights Conference On May 10

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr.

Arrowhead Research Announces RNAi Leader John J. Rossi, Ph.D. To Join Calando Scientific Advisory Board

Arrowhead Research Announces RNAi Leader John J. Rossi, Ph.D. To Join Calando Scientific Advisory Board

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that John J.

Arrowhead Research Increases Ownership In Ablaris To 64%

Arrowhead Research Increases Ownership In Ablaris To 64%

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity and regenerative medicine, today announced that majority-owned subsidiary Ablaris Therapeutics, Inc.

Arrowhead Research To Present At The Roth Capital Partners 23rd Annual OC Growth Stock Conference On March 16

Arrowhead Research To Present At The Roth Capital Partners 23rd Annual OC Growth Stock Conference On March 16

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that Dr.

Arrowhead Reports Fiscal 2011 First Quarter Financial Results

Arrowhead Reports Fiscal 2011 First Quarter Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced financial results for its fiscal 2011 first quarter...

Arrowhead Research To Present At The 13th Annual BIO CEO & Investor Conference

Arrowhead Research To Present At The 13th Annual BIO CEO & Investor Conference

Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company, today announced that Dr.

Arrowhead Research To Report Fiscal 2011 First Quarter Financial Results And Host Conference Call On Thursday, February 10, 2011

Arrowhead Research To Report Fiscal 2011 First Quarter Financial Results And Host Conference Call On Thursday, February 10, 2011

Arrowhead Research Corporation (NASDAQ: ARWR), a focused nanomedicine holding company, today announced that it will report its financial results for the fiscal 2011 first quarter ended December 31, 2010, on Thursday,...

Arrowhead Subsidiary Unidym, Inc. Acquired By Wisepower Co., Ltd. For Up To $140 Million Earn-Out Plus $5 Million Upfront

Arrowhead Subsidiary Unidym, Inc. Acquired By Wisepower Co., Ltd. For Up To $140 Million Earn-Out Plus $5 Million Upfront

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its Unidym, Inc.

Arrowhead Increases Investment In RNAi Subsidiary Calando Pharmaceuticals

Arrowhead Increases Investment In RNAi Subsidiary Calando Pharmaceuticals

Arrowhead Research Corporation (NASDAQ: ARWR) (“the Company”) today announced that it has invested $1 million in its majority owned subsidiary, Calando Pharmaceuticals, and converted approximately $8M of ...

8 Penny Stocks Get Delisting Warning

8 Penny Stocks Get Delisting Warning

Another round of small-cap companies are on watch by the Nasdaq and NYSE to be delisted in six months.

Arrowhead Research CEO Discusses F4Q2010 Results – Earnings Call Transcript

Arrowhead Research CEO Discusses F4Q2010 Results – Earnings Call Transcript

Arrowhead Research CEO Discusses F4Q2010 Results â¿¿ Earnings Call Transcript

Arrowhead Reports Fiscal 2010 Fourth Quarter And Year-End Financial Results

Arrowhead Reports Fiscal 2010 Fourth Quarter And Year-End Financial Results

Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2010 fourth quarter and year ended September 30, 2010.

Arrowhead Starts New Subsidiary, Ablaris Therapeutics, To Commercialize Anti-Obesity Technology

Arrowhead Starts New Subsidiary, Ablaris Therapeutics, To Commercialize Anti-Obesity Technology

Arrowhead Research Corporation (NASDAQ: ARWR) (“Arrowhead” or the “Company”) today announced that it has executed an exclusive world-wide license on technology developed by Drs.

Arrowhead Research To Report Fiscal 2010 Fourth Quarter And Year-End Financial Results And Host Conference Call On Wednesday, December 22, 2010

Arrowhead Research To Report Fiscal 2010 Fourth Quarter And Year-End Financial Results And Host Conference Call On Wednesday, December 22, 2010

Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2010 fourth quarter and year ended September 30, 2010, on Wednesday, December 22, 2010 at 4:30 p.

Arrowhead CEO Provides Perspective On $4.5 Million Alliance Between Subsidiary Unidym And Samsung Electronics

Arrowhead CEO Provides Perspective On $4.5 Million Alliance Between Subsidiary Unidym And Samsung Electronics

Arrowhead Research Corporation’s (NASDAQ: ARWR) (“the Company”) President and Chief Executive Officer today issued the following open letter to the Company’s shareholders: Dear...

Unidym Announces Alliance With Samsung Electronics

Unidym Announces Alliance With Samsung Electronics

Unidym, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that it has completed IP cooperation and license agreements with Samsung Electronics Co.

TheStreet Quant Rating: C+ (Hold)